2.37
0.00%
0.00
After Hours:
2.37
Oramed Pharmaceuticals Inc stock is traded at $2.37, with a volume of 52,904.
It is up +0.00% in the last 24 hours and up +3.49% over the past month.
See More
Previous Close:
$2.37
Open:
$2.37
24h Volume:
52,904
Relative Volume:
0.54
Market Cap:
$91.73M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
-4.6471
EPS:
-0.51
Net Cash Flow:
$-10.55M
1W Performance:
+1.28%
1M Performance:
+3.49%
6M Performance:
+8.72%
1Y Performance:
+7.73%
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.37 | 91.73M | 2.70M | 5.53M | -10.55M | 0.14 |
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
Apr-20-21 | Initiated | Canaccord Genuity | Buy |
Feb-09-21 | Initiated | National Securities | Buy |
Dec-03-20 | Initiated | Alliance Global Partners | Buy |
Mar-11-20 | Initiated | Aegis Capital | Buy |
Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
May-26-16 | Reiterated | FBR Capital | Outperform |
Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
Nov-19-15 | Initiated | FBR Capital | Outperform |
Apr-13-15 | Resumed | MLV & Co | Buy |
Jan-30-14 | Reiterated | Aegis Capital | Buy |
Jan-08-14 | Reiterated | Aegis Capital | Buy |
Jan-08-14 | Initiated | MLV & Co | Buy |
Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving AverageTime to Sell? - MarketBeat
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Holdings Lifted by BML Capital Management LLC - MarketBeat
Type 1 Diabetes Market Future Business Opportunities 2024-2031 - openPR
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M - Simply Wall St
Oramed Announces Additional $1M Payment on Tranche A Note By Investing.com - Investing.com South Africa
Oramed Announces Additional $1M Payment on Tranche A Note - Investing.com India
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to "Hold" at StockNews.com - MarketBeat
ORAMED PHARMACEUTICALS INC. Refinances with New Securities Purchase Agreement - MarketBeat
Oramed Pharmaceuticals Reinforces Scilex Financial Ties - TipRanks
Scilex Holding extends payment deadline in Oramed agreement - Investing.com India
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PR Newswire
Scilex Holding Company Announces Signing of a $50 Million - GlobeNewswire
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy by StockNews.com - MarketBeat
Tranche Update on Oramed Pharmaceuticals Inc.'s Equity Buyback Plan announced on June 26, 2024. - Marketscreener.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Bought by Murchinson Ltd. - MarketBeat
Oramed signs $11.5 million deal for clinical trial services By Investing.com - Investing.com South Africa
Oramed signs $11.5 million deal for clinical trial services - Investing.com
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: - openPR
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: Therapies, Clinical Trials, and MOA, ROA by DelveInsight | Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed - Barchart
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to Hold - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Scilex Holding agrees to payment terms with Oramed Pharmaceuticals - Investing.com India
Oramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21 - MSN
Moors & Cabot Inc. Buys 164 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Oriole Resources (LON:ORR) Shares Down 2.3% - Defense World
Sidoti Csr Weighs in on Orion Group Holdings, Inc.’s Q3 2024 Earnings (NYSE:ORN) - Defense World
Oral Biologics Market 2024-2031 Industry Size Forecast: Growth - openPR
O'Reilly Automotive, Inc. (NASDAQ:ORLY) Position Raised by E Fund Management Co. Ltd. - MarketBeat
BMO Capital Markets analysts downgrades a Market perform rating for Ionis Pharmaceuticals Inc (IONS) - Knox Daily
Wealthspire Advisors LLC Buys 12 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
OMIC’s Market Whiplash: -10.31% YTD Decline, 69.47% Rise in 30 Days - The InvestChronicle
Ashton Thomas Private Wealth LLC Takes Position in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
O’Reilly Automotive, Inc. (NASDAQ:ORLY) Shares Purchased by Acadian Asset Management LLC - Defense World
Private Advisor Group LLC Has $2.56 Million Stake in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Research Analysts Set Expectations for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP) - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to “Hold” - Defense World
Comprehensive Study of Oral Biologics Market 2024-2031 - openPR
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to "Hold" at StockNews.com - MarketBeat
Oramed Pharmaceuticals’ (ORMP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Neutral rating on Oramed amid ongoing NMPA review - Investing.com India
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Brokers Offer Predictions for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP) - MarketBeat
ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by StockNews.com to Buy - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below Two Hundred Day Moving Average of $2.58 - MarketBeat
Future Scope of Oral Biologics Market Overall Study Report - openPR
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):